Pelthos Therapeutics Inc. SEC filings PTHS

Pelthos Therapeutics Inc. has 253 filings in SEC EDGAR's recent list, going back to Sep 6, 2022. Its latest annual report, Form ARS, was filed on Aug 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (material agreement, new debt, unregistered share sale, change to shareholder rights, officer or director change, bylaw or fiscal year change, shareholder vote results, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
10-Q/A Amended quarterly report Aug 13, 2026 Mar 31, 2026
10-Q Quarterly report May 14, 2026 Mar 31, 2026
10-Q Quarterly report Nov 13, 2025 Sep 30, 2025
10-Q Quarterly report Aug 13, 2025 Jun 30, 2025
10-Q Quarterly report May 13, 2025 Mar 31, 2025
10-Q Quarterly report Nov 13, 2024 Sep 30, 2024
10-Q Quarterly report Aug 13, 2024 Jun 30, 2024
10-Q Quarterly report May 15, 2024 Mar 31, 2024

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
PTHS (NYSE)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Durham, NC
SEC filer status
, Emerging growth company
SEC CIK
1919246
Former names
Channel Therapeutics Corp (until May 27, 2025); Chromocell Therapeutics Corp (until Nov 15, 2024)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.